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doi:10.1016/j.jmii.2011.01.010Background: Etanercept has been shown to be an effective treatment for juvenile idiopathic
arthritis (JIA). In this study, we evaluated the effectiveness of etanercept therapy in the treat-
ment of refractory JIA.
Methods: This was a retrospective analysis of 11 patients with refractory JIA (polyarticular
type nZ 7; pauciarticular type, nZ 2; systemic type, nZ 2) who received treatment with
etanercept during the period 2005e2009 in a medical center. The indications for etanercept
treatment included persistent fever, arthritis/arthralgia, or elevated levels of inflammatory
mediators after treatment with methotrexate and/or prednisolone for more than 6 months.
The patients were treated with etanercept (0.4 mg/kg, with maximal 25 mg, subcutaneously,
twice a week) for a total of 12 months.
Results: The degree of arthritis/arthralgia improved (range of motion and painful sensation
of involved joints), and the levels of inflammatory markers (C-reactive protein and eryth-
rocyte sedimentation rate) decreased progressively in 10 of the 11 patients (p < 0.05) at
1-, 3-, 5-, and 12-month follow-up after treatment with etanercept. Mean hemoglobin
levels significantly increased, whereas mean platelet counts decreased after etanercept
treatment (p < 0.05). Only one patient with systemic type of JIA failed to respond to the
treatment after 6 weeks of etanercept therapy. Methotrexate, prednisolone, and other
immunosuppressive drugs were successfully discontinued after a mean of 2.5 months
(range, 1e5 months) of etanercept therapy in the 10 patients who responded to etanercept
treatment.t of Medical Research and Pediatric Allergy, Immunology and Rheumatology, Chang Gung Memorial
3 Ta-Pei Road, Niaosung, Kaohsiung, Taiwan.
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Juvenile idiopathic arthritis (JIA) is the most common
rheumatic disease in childhood. It is a diagnosis of exclusion
and defined as arthritic symptoms of unknown etiology
lasting for at least 6 weeks in patients younger than 16
years. Approximately 30% of patients respond to the
nonsteroidal anti-inflammatory drugs and an appropriate
program of physical therapy. Most patients, however,
require more aggressive therapy with antirheumatic drugs.
JIA can lead to severe disability and is associated with life-
threatening complications, particularly in patients who do
not respond to conventional treatment.1e3 Although JIA has
been divided into subtypes, we are still unable to identify
those children who will benefit from more aggressive
therapy. Most patients with systemic- or polyarticular-onset
JIA need other second-line medications. Hydroxychloroquine
and methotrexate (MTX) have been shown to be effective
alternatives to nonsteroidal anti-inflammatory drugs. Al-
though glucocorticoids are effective in treating JIA, long-
term administration can lead to undesired side effects such
as short stature. MTX (10 mg/m2/wk) is the standard treat-
ment regimen for JIA. The patients who do not respond to
MTX after 6 months of treatment are classified as having
refractory JIA.4 In such cases, therapies involving combina-
tions of MTX with corticosteroids or other immunosuppres-
sive drugs, such as D-penicillamine, gold compounds, or
cyclophosphamide, should be considered.
Biological agents, such as etanercept and infliximab,
have recently been shown to be effective in the treatment
of refractory JIA.4 Etanercept, a recombinant human
soluble p75 tumor necrosis factor receptor that binds to
tumor necrosis factor-alpha and renders it biologically
unavailable, has been shown to be effective and well
tolerated in patients with rheumatoid arthritis.5,6 Results
from a multicenter pediatric trial performed in the United
States showed that etanercept was effective and well
tolerated in 74% of children (nZ 69) with JIA regardless of
the subtypes of disease.7 In the present study, we retro-
spectively evaluated the effectiveness of etanercept
treatment in Taiwanese patients with JIA refractory to MTX
and/or prednisolone. We also evaluated when MTX and/or
prednisolone should be tapered or discontinued after
initiation of etanercept treatment. The effectiveness of
etanercept was determined by comparing the dynamic
changes in inflammatory markers (C-reactive protein [CRP]
and erythrocyte sedimentation rate [ESR]) and complete
blood counts at baseline with those at 1, 3, 5, and 12
months after etanercept treatment.
Methods
We evaluated the effectiveness of etanercept in 11
consecutive patients in whom refractory JIA had been
diagnosed at the Chang Gung Memorial HospitaleKaohsiungMedical Center based on the International League of Asso-
ciations for Rheumatology classification criteria for JIA.1
Among the 11 children, 7 patients had polyarticular type of
JIA, 2 patients had pauciarticular type of JIA, and 2 patients
had systemic onset of JIA. All the children had persistent
fever, arthritis/arthralgia, or high levels of inflammatory
mediators (CRP and/or ESR) after treatment with MTX
(>10 mg/m2/wk) and/or prednisolone (0.25 mg/d/kg) for
more than 6 months. The patients were treated with eta-
nercept (0.4 mg/kg, with maximal 25 mg, subcutaneously,
twice a week) for 12 months. Complete blood count
(including total white blood cell counts, platelet counts, and
hemoglobin levels), aspartate aminotransferase (AST) levels,
alanine aminotransferase (ALT) levels, CRP levels, and ESR,
which had been measured 1 month before etanercept
treatment (baseline) and at 1, 3, 5, and 12 months after the
treatment began, were obtained from the medical records.
Body height (BH) from one patient who received etanercept
for more than 40 months was also included to evaluate the
kinetic change in height after etanercept treatment. The
study protocol was approved by the institutional review
board of the Chang Gung Memorial Hospital.
Statistical analysis
Laboratory values are presented as mean standard error.
Significant differences in levels of CRP, ESR, AST, ALT, total
WBC, hemoglobin, and platelets at baseline and after
treatment with etanercept were tested by a paired-sample
t test. A p value of less than 0.05 was considered statisti-
cally significant. All statistical tests were performed using
SPSS 12.0 for Windows XP (SPSS Inc., Chicago, IL, USA).8
Results
A total of 11 patients (5 boys and 6 girls) with JIA refractory
to MTX and/or prednisolone received etanercept treat-
ment. Rheumatoid factor was positive in two patients
(18.2%, 2/11), anti-nuclear antibody was positive in four
patients (36.4%, 4/11), and human leukocyte antigen-B27
was positive in three patients (33%, 3/9). The mean age at
diagnosis of JIA was 103.6 months, and the mean age of
patients when etanercept therapy began was 124.6 months
(Table 1).
MTX and/or prednisolone were tapered and discontinued
at a mean of 2.52 months (range, 1e5 months) after
starting etanercept treatment. At Month 5 of the treatment
protocol, all the patients were being treated with eta-
nercept therapy alone. There were no adverse effects and
cases of atypical mycobacteria infection, diarrhea, sepsis,
or cellulitis during the follow-up period. Elevated liver
enzyme levels (AST, 90 U/L; ALT, 86 U/L) were noted after
1.5 months of etanercept therapy in one patient with upper
respiratory tract infection (Patient 7). The liver enzyme
levels had returned to normal at 3-month follow-up.
Table 1 Demographic data of juvenile idiopathic arthritis patients who received etanercept treatment
Case Gender Subtype Age (diagnosis) Age (Enbrel) DMARDs Corticosteroid RF ANA HLA-B27
1 M Poly 7 yr 5 mo 14 yr 2 mo MTX þ   
2 F Poly 9 yr 9 yr 6 mo MTX þ  þ 
3 F Systemic 1 yr 9 mo 7 yr 2 mo MTXþ Cyc þ  
4 M Poly 9 yr 2 mo 9 yr 9 mo MTX þ  þ þ
5 F Poly 4 yr 4 mo 6 yr 1 mo MTX þ  
6 M Pauci 12 yr 10 mo 13 yr 11 mo MTXþ AZAþ
intra-articular
þ   þ
7 F Systemic 14 yr 11 mo 15 yr 8 mo MTX þ þ  
8 M Poly 10 yr 6 mo 11 yr MTX þ   
9 F Poly 4 yr 2 mo 4 yr 8 mo MTX þ  þ 
10 F Poly 5 yr 5 mo 6 yr 8 mo MTX þ þ þ 
11 M Pauci 14 yr 8 mo 15 yr 10 mo MTX þ   þ
ANAZ anti-nuclear antibody; AZAZ azathioprine; CycZ cyclosporine; FZ female; HLA-B27Z human leukocyte antigen-B27; Intra-
articularZ intra-articular corticosteroids injection; MZmale; MTXZmethotrexate; PauciZ pauciarticular type of JIA; PolyZ
polyarticular type; RFZ rheumatoid factor; SystemicZ systemic type of JIA.
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and ESR during the 12-month follow-up period (p< 0.05;
Table 2). Persistent fever and arthritic symptoms at Week 6
of etanercept therapy occurred in one child (Patient 3) with
systemic-onset JIA. Etanercept was discontinued, and the
patient was treated with intravenous immunoglobulin and
methylprednisolone pulse therapy; however, she still
showed poor response. Hemoglobin levels significantly
increased (p< 0.05) in all the patients with the exception
of Patient 3, who failed to respond to etanercept therapy,
and Patient 5, who had thalassemia. Mean WBC counts at 1-
month follow-up were significantly lower than at baseline
(Table 2). The dynamic changes in CRP, ESR, platelet, and
hemoglobin during the 12-month follow-up period are
shown in Fig. 1AeD. Platelet counts, CRP levels, and ESR
significantly decreased after etanercept treatment in all
the patients with the exception of the patient who failed to
respond to the treatment.
For 15 months before the induction of etanercept
treatment, Patient 1 had been treated with disease-modi-
fying anti-inflammatory drugs and prednisolone. During
that time period, the patient gained only 5 cm in height.
After 40 months of etanercept treatment, however, Patient
1 gained 20 cm in height. In the four patients who had
received etanercept treatment for less than 40 months andTable 2 The dynamic change of laboratory data before and aft
Before etanercept
treatment
1 mo after
etanercept
treatment
pb 3
e
t
WBC (103/mm3) 9.0 0.9 6.9 0.6 0.044*
Hemoglobin (g/dL) 11.4 0.44 12.4 0.49 0.009* 1
Platelet (104/mm3) 38.2 2.7 28.7 1.8 0.013* 3
CRP (mg/dL) 35.1 11.3 6.7 3.0 0.02* 3
ESR (mm/hr) 26.4 3.7 14.9 2.5 0.015*
a Data are presented as mean  standard error.
b The p values were tested by paired-sample t test and nonparam
etanercept treatment. (nZ 10, excluded Patient 3 who failed to r
statistical significant.
CRPZ C-reactive protein; ESRZ erythrocyte sedimentation rate; WBfor whom BH data were available, the gain in height
significantly increased from a mean of 3.5 0.96 cm before
treatment to a mean of 7.5 0.94 cm 10 months after the
initiation of etanercept treatment (p< 0.05).
Discussion
Despite the advantages of MTX over other conventional
immunosuppressive agents, many patients receiving MTX
experience at least some degree of toxicity.9 The most
common adverse events in the preefolate supplementation
era included nausea, vomiting, and mucous membrane
ulceration.10 Rare but serious adverse effects, such as hepa-
totoxicity, pneumonitis, opportunistic infections, and the
development of certain types of malignancies (e.g. non-
Hodgkin lymphoma) have been shown to be associated with
MTX therapy.9e12 Therefore, etanercept provides the oppor-
tunity to discontinue MTX and decreases the potential toxic-
ities. Placebo-controlled trials and long-term prospective
studies on JIA have shown thatMTX is less effective in children
than in adults.13e16 MTX is not effective or well tolerated in
some patients with JIA, and higher doses of MTX may be
associated with greater toxicity.17
Etanercept is safe and well tolerated.18 In our study,
there were no deaths and adverse reactions to the drug.er etanercept treatmenta
mo after
tanercept
reatment
pb 5 mo after
etanercept
treatment
pb 12 mo after
etanercept
treatment
pb
7.3 0.5 0.089 7.0 0.7 0.105 7.5 0.3 0.06
2.4 0.52 0.031* 12.4 0.46 0.008* 12.8 0.68 0.037*
0.1 2.2 0.012* 27.8 2.0 0.002* 26.5 1.96 0.002*
.25 1.0 0.017* 1.82 0.6 0.016* 1.3 0.5 0.03*
9.6 1.4 0.001* 10.0 3.1 0.006* 6.1 0.9 0.001*
etric test. All the p values were tested with values from before
espond to etanercept during 6 weeks of treatment); *p< 0.05,
CZwhite blood cell count.
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Figure 1. (A) CRP level, (B) ESR, and (C) platelet counts significantly decreased after etanercept treatment during a 12-month
follow-up in all patientswith the exception of Patient 3who responded poorly to etanercept treatment. Treatment in that patientwas
discontinued after 6 weeks. (D) Hemoglobin levels during 12 months of etanercept treatment significantly increased in all patients
with the exception of Patient 3 and Patient 5,who had thalassemia. CRPZC-reactive protein; ESRZ erythrocyte sedimentation rate.
Etanercept in JIA treatment 55Treatment was discontinued in one patient because of
fever and persistent symptoms after etanercept treatment
for 6 weeks. In another patient, AST and ALT were ele-
vated after four doses of etanercept; however, the
increase in liver enzyme levels was because of underlying
upper respiratory tract infection and not because of eta-
nercept treatment. Liver enzyme levels returned to within
normal range after the infection resolved. The findings
from this study provide further evidence that etanercept is
a safe and an effective agent for the treatment of
refractory JIA.
To the best of our knowledge, no studies have investi-
gated the optimal timing in which MTX and/or prednisolone
can be tapered or discontinued after etanercept treat-
ment. Based on our findings, we suggest that disease-
modifying anti-inflammatory drugs and prednisolone can be
ceased within 5 months after initiation of etanercept
treatment. All the patients who responded to etanercept
continued to respond to etanercept after MTX and/or
prednisolone had been discontinued. Large-scale multi-
center trials are needed to confirm our findings.Vojvodich et al.19 reported that etanercept improves
body growth in most patients with JIA.5 In our study, there
was a significant increase in mean BH after etanercept
treatment. Further investigation with long-term follow-up is
needed to clarify the association between etanercept
treatment and changes in BH. There were only few case
reports of etanercept treatment for refractory JIA in Taiwan;
here, we reported our experience of etanercept treatment
for 11 refractory JIA.20,21
In conclusion, etanercept is beneficial for patients with
polyarticular and pauciarticular type of JIA that is refrac-
tory to conventional treatment but less beneficial for
systemic type of JIA.Acknowledgments
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